Trend over time of HIV-1 drug resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and their drivers: A cohort study from Antiviral Response Cohort Analysis (ARCA).
HAART
HIV-1
NNRTIs
RAMs
antiretroviral therapy
resistance
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
28
02
2023
accepted:
19
06
2023
medline:
16
11
2023
pubmed:
13
7
2023
entrez:
13
7
2023
Statut:
ppublish
Résumé
The rise of HIV-1 drug resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) threatens the long-term success of NNRTI-based therapies. Our study aims to describe the circulation of major resistance-associated mutations (RAMs) for NNRTIs in people living with HIV (PLWH) in Italy from 2000 to 2020. We included 5982 naïves and 28 505 genotypes from 9387 treatment-experienced PLWH from the Antiviral Response Cohort Analysis (ARCA) cohort. Transmitted drug resistance (TDR) was found in 12.5% and declined from 17.3% in 2000-2003 to 10.9% in 2016-2020 (p = 0.003). Predictors of TDR were viral subtype B [vs. non-B, adjusted odds ratio (aOR) = 1.94, p < 0.001], zenith viral load (VL) (per 1 log
Substances chimiques
Reverse Transcriptase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1150-1157Informations de copyright
© 2023 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.
Références
European AIDS Clinical Society (EACS) Guidelines. Version 11.1, October 2022. Available at: https://www.eacsociety.org/guidelines/eacs-guidelines/
Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2021;396(10267):1994-2005. doi:10.1016/s0140-6736(20)32666-0
Iannone V, Farinacci D, D'Angelillo A, et al. Cardiovascular disease risk in a cohort of Virologically suppressed people living with HIV switching to Doravirine: preliminary data from the real life. AIDS Res Hum Retroviruses. 2022;38(11):878-880. doi:10.1089/AID.2022.0050
World Health Organisation (WHO). HIV Drug Resistance Report 2021. Avalilable at: https://www.aidsdatahub.org/sites/default/files/resource/who-hiv-drug-resistance-report-2021.pdf.
Antiviral Response Cohort Analysys. ARCA database. Available at https://www.dbarca.net/
HIV Drug Resistance. HIV drug resistance report 2021. World Health Organization; 2021 Available at: https://apps.who.int/iris/rest/bitstreams/1394483/retrieve
Wensing AM, Calvez V, Ceccherini-Silberstein F, et al. Update of the Drug Resistance Mutations in HIV. International Antiviral Sociey-USA (IAS-USA) 2022. 2022 https://www.iasusa.org/resources/hiv-drug-resistance-mutations/
HIV Drug Resistance Mutations Database, Stanford University. Version 8.9-1, November 2019. Available at: https://cms.hivdb.org/prod/downloads/asi/HIVDB_8.9-1.xml
HIValg Program: Sequence analysis, Stanford University. Version 8.9.1, November 2019. Available at: https://hivdb.stanford.edu/hivalg/by-sequences
Jain V, Sucupira MC, Bacchetti P, et al. Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis. 2011;203(8):1174-1181. doi:10.1093/infdis/jiq167
Miranda MNS, Pingarilho M, Pimentel V, et al. Trends of transmitted and acquired drug resistance in Europe from 1981 to 2019: a comparison between the populations of late presenters and non-late presenters. Front Microbiol. 2022;13(13):846943. doi:10.3389/fmicb.2022.846943
Pham HT, Xiao MA, Principe MA, Wong A, Mesplède T. Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection. Drugs Context. 2020;9:2019-11-4. doi:10.7573/dic.2019-11-4
Asante-Appiah E, Lai J, Wan H, et al. Impact of HIV-1 resistance-associated mutations on susceptibility to Doravirine: analysis of real-world clinical isolates. Antimicrob Agents Chemother. 2021;65(12):e0121621. doi:10.1128/AAC.01216-21
Taramasso L, Lo Caputo S, Magnasco L, et al. Long-term effectiveness of Rilpivirine-based single-tablet regimens in a seven-year, two-center observational cohort of people living with HIV. AIDS Res Hum Retroviruses. 2022 Jun;38(6):472-479. doi:10.1089/AID.2021.0161
Rizzardini G, Overton ET, Orkin C, et al. Long-acting injectable cabotegravir + Rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials. J Acquir Immune Defic Syndr. 2020;85(4):498-506. doi:10.1097/QAI.0000000000002466
Nijhuis M, Deeks S, Boucher C. Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis. 2001;14(1):23-28. doi:10.1097/00001432-200102000-00005
Rossetti B, di Giambenedetto S, Torti C, et al. Antiviral response cohort analysis (ARCA) collaborative group. Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016. HIV Med. 2018;19(9):619-628. doi:10.1111/hiv.12640
Bracciale L, Colafigli M, Zazzi M, et al. Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors. J Antimicrob Chemother. 2009;64(3):607-615. doi:10.1093/jac/dkp246
Bavaro DF, Di Carlo D, Rossetti B, et al. Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA. Antivir Ther. 2020;25(2):61-71. doi:10.3851/IMP3349
Yebra G, de Mulder M, del Romero J, Rodríguez C, Holguín A. HIV-1 non-B subtypes: high transmitted NNRTI-resistance in Spain and impaired genotypic resistance interpretation due to variability. Antiviral Res. 2010;85(2):409-417. doi:10.1016/j.antiviral.2009.11.01